Search

Syndax Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

20.05 0.6

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

19.62

Макс.

20.14

Ключевые показатели

By Trading Economics

Доход

-6.7M

-49M

Продажи

7.9M

73M

Прибыль на акцию

-0.55

Рентабельность продаж

-67.817

Сотрудники

298

EBITDA

-5.9M

-37M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+85.81% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

43M

1.7B

Предыдущая цена открытия

19.45

Предыдущая цена закрытия

20.05

Новостные настроения

By Acuity

54%

46%

283 / 340 Рейтинг в Healthcare

Syndax Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 авг. 2026 г., 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 авг. 2026 г., 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 авг. 2026 г., 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 авг. 2026 г., 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 авг. 2026 г., 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 авг. 2026 г., 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 авг. 2026 г., 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 авг. 2026 г., 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 авг. 2026 г., 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 авг. 2026 г., 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

10 авг. 2026 г., 19:36 UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

6 авг. 2026 г., 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

5 авг. 2026 г., 20:02 UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

4 авг. 2026 г., 23:11 UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

3 авг. 2026 г., 19:16 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

31 июл. 2026 г., 20:06 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

30 июл. 2026 г., 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 июл. 2026 г., 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 июл. 2026 г., 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 июл. 2026 г., 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 июл. 2026 г., 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 июл. 2026 г., 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Сравнение c конкурентами

Изменение цены

Syndax Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

85.81% рост

Прогноз на 12 месяцев

Средняя 37.33 USD  85.81%

Максимум 57 USD

Минимум 26 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Syndax Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

10

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

283 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat